@article{af8f8bf1752a48da8f1a06ee3c045274,
title = "Change in albuminuria as a surrogate endpoint in chronic kidney disease – Authors' reply",
author = "Heerspink, {Hiddo J.L.} and Josef Coresh and Gansevoort, {Ron T.} and Inker, {Lesley A.}",
note = "Funding Information: HJLH reports grants from the US National Kidney Foundation (NFK); grants and other support from AbbVie, AstraZeneca, Boehringer Ingelheim, and Janssen; and other support from Astellas, Fresenius, Gilead, and Merck. JC reports grants from NFK and the US National Institutes of Health (NIH). LAI reports grants from NIH and NKF; funding from NIH, NKF, Retrophin, Omeros, and Reata Pharmaceuticals (research and contracts [Tufts Medical Center]); and consulting agreements with Tricida and Omeros. LAI also reports a provisional patent (filed Aug 15, 2014; precise estimation of glomerular filtration rate from multiple biomarkers, patent no PCT/US2015/044567), and Tufts Medical Center, John Hopkins University, and Metabolon have a collaboration agreement to develop a product to estimate glomerular filtration rate from a panel of markers. RTG reports no competing interests.",
year = "2019",
month = may,
doi = "10.1016/S2213-8587(19)30080-4",
language = "English (US)",
volume = "7",
pages = "336--337",
journal = "The Lancet Diabetes and Endocrinology",
issn = "2213-8587",
publisher = "Elsevier BV",
number = "5",
}